Related Experiment Video
Updated: May 19, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Premenopausal antimüllerian hormone concentration is associated with subsequent atherosclerosis
Susan E Appt1, Haiying Chen, Thomas B Clarkson
1Wake Forest Primate Center and Department of Pathology/Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157-1040, USA. sappt@wakehealth.edu
Objective:
The aim of this study was to determine if premenopausal ovarian reserve is associated with susceptibility for atherosclerosis.
Methods:
Female cynomolgus macaques (n = 66, women's equivalent age = 45 y) consumed an atherogenic diet for ∼5 months before the measurement of a marker of ovarian reserve (antimüllerian hormone [AMH]), plasma lipids, follicular phase estradiol, and body weight (BW). Monkeys were then ovariectomized (OVX; n = 17), remained premenopausal (n = 20), or were induced to have reduced ovarian reserve (ROR, n = 29). After 26 additional months consuming the diet, atherosclerosis measurements and risk variables were reassessed.
Results:
No differences in baseline AMH, plasma lipids, BW, and estradiol or postdiet lipids and BW were observed among the groups subsequently assigned to the OVX, premenopausal control, or reduced ovarian reserve conditions. Postdiet measurements of atherosclerosis extent did not differ among the groups. However, analysis of plaque size by tertile of baseline AMH revealed that plaques were largest in monkeys that began the experiment with the lowest baseline AMH, followed by those in the middle and high tertiles (plaque extent: low AMH, 0.76 ± 0.12 mm; mid AMH, 0.46 ± 0.1 mm; high AMH, 0.34 ± 0.08 mm; P = 0.02). Baseline AMH and plaque size were also correlated negatively (r = -0.31, P = 0.01). Plasma lipids were also correlated significantly with plaque extent (all P < 0.01) but not with AMH.
Conclusions:
We report for the first time an inverse relationship between a marker of ovarian reserve (AMH) and subsequent atherosclerosis risk.
Related Concept Videos
Atherosclerosis III: Management
Atherosclerosis I: Introduction
Menopause
Coronary Artery Disease I: Introduction
Inflammation
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
